Tracking #SARSCoV2 #Lineages - Globally
Top lineages -#20DayTrends (#G20):
XBB.1.5 (48.1%)⬆️
XBB.1.9.1 (6.5%)⬆️
CH.1.1 (3.6%)
BQ.1.1 (2.6%)
EG.1 (2.4%)⬆️
CH.1.1.1 (2.1%)
..
XBB.1.16 (1.6%)👀
** includes Spike only seqs
Tracker: public.tableau.com/app/profile/ra…
Updt 03/26/23
Granular details #Global #20DayTrends
This analysis includes all designated #SARSCoV2 sequences submitted to GISAID with sample collection dates on or after 03/06/2023 (25,590 sequences)
Contains many spike sequences from Austria
#USA, #UnitedKingdom & #Austria have submitted a lion's share of sequences with sample collection dates on or after 03/06/2023 ...followed by #Canada, #Germany, #Denmark, #Australia, #Italy, #France, #Nertherlands, #India, #Poland
In Silico Immune escape and ACE2 receptor binding scores (relative to BA.2)*
Data is intended to prioritize select lineages to generate rapid laboratory experiments to gauge immune escape and ACE2 binding affinity.
[Credits in the legend]
* Only Spike RBD mutations considered
Predicted Immune escape and ACE2 receptor binding scores (relative to BA.2)* of #SARSCoV2 Recombinant lineages
#SARSCoV2 lineages in the zone of concern (red box) - Predicted to have high immune escape and tight ACE2 binding activity - A Closer look
Chart: public.tableau.com/app/profile/ra…
What to expect in the next few weeks?
github.com/neherlab/SARS-…
Excellent SARSCoV2 Variant report
H/T @richardneher @CorneliusRoemer
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.